ArticleTobacco induced diseases2025
Clustering analysis of volatile organic compound biomarkers with tobacco exposure and the association with cardiovascular health outcomes in an observation study cohort.
Article in Tobacco induced diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVolatile organic compounds (VOCs) are toxic compounds found in tobacco smoke. Despite research on cigarette generated single VOCs, scant evidence exists on the mixtures of VOCs associated with different tobacco products. We aimed to explore whether distinct VOC exposure profiles exist among users of combustible cigarettes, e-cigarettes, and non-users, and to assess their associations with cardiovascular (CV) health markers.
methodsParticipants who self-reported use of e-cigarettes, cigarettes, or no tobacco (n=348; mean age 26 ± 7 years) enrolled in The Cardiovascular Injury due to Tobacco Use (CITU) 2.0 study from July 2018 to July 2023 at two US sites (Boston, MA, and Louisville, KY). VOC metabolites were analyzed in urine one-hour post-use of a tobacco product via ultraperformance liquid chromatography. We applied unsupervised K-Means clustering on the creatinine-adjusted VOC metabolite data and explored the association between each cluster and blood pressure, adjusting for age, sex, and race.
resultsThe clustering analysis identified two distinct clusters. Cluster 1 (302 individuals, 86.8%) was characterized by low VOC metabolite levels with individuals predominantly e-cigarette users (59.3%), non-users (29.1%), and a smaller proportion of cigarette smokers (11.6%). Cluster 2 (46 individuals, 13.2%) had higher levels of VOC metabolites including CYMA, HPMMA, MHBMA3, and 3HPMA, and included most of the individuals who used cigarettes (91.3%). After adjustment for age, sex, and race, Cluster 2 was associated with a higher heart rate (β=3.29; 95% CI: -0.26-6.84; p<0.05) compared to Cluster 1. No significant differences were observed for systolic (β= -0.66; 95% CI: -4.60-3.28) or diastolic blood pressure (β=0.34; 95% CI: -2.51-3.2) between clusters.
conclusionsThese findings suggest that cigarette-induced VOC exposure may not impact cardiovascular function after acute exposure. Additionally, VOC exposure profiles vary across tobacco product types, suggesting that regulatory assessments of tobacco products could consider exposure patterns rather than product types. Clustering analyses may offer a powerful tool to assess the safety and risks of new and emerging tobacco products based on real-world exposure patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.